Close Menu

Parkinson's disease

The partners will use Microba's technologies to examine the link between the gut microbiome and Parkinson's disease in animal models and in patients.

In PLOS this week: potential neuropsychiatric drug targets identified, analysis of foodborne pathogen genome, and more.

The bioinformatics and sequencing firm, formerly known as WuXi NextCode, will develop a population clinicogenomic database to support Emory's research.

The companies aim to identify biomarkers that can be used to diagnose early-onset Parkinson's disease, as well as track disease progression.

In PLOS this week: differential transcript usage and splicing among Parkinson's disease patients, search for markers of intracranial aneurysms, and more.

The drugmaker has a small molecule drug called venglustat under Phase II development for Parkinson's disease patients with a specific genetic mutation.

The transcriptomic study of human iPSC-derived dopaminergic neurons elucidated how gene expression changed in response to cytotoxic and genetic stressors.

In PLOS this week: no enrichment of rare variants among Parkinson's disease patients in associated genes, circulating tumor DNA helps guide metastatic breast cancer patient management, and more.

In Science this week: additional variants linked to development of primary lymphedema, and more.

The partners will leverage MedGenome's database of genetic variants in South Asians to identify and analyze genes and variants associated with Parkinson's disease.

Pages

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

A new analysis suggests the B.1.1.7 strain of SARS-CoV-2 could be deadlier than previous ones, according to the Guardian.

NPR reports Merck is halting the development of its two candidate SARS-CoV-2 vaccines following disappointing Phase 1 results.

In PLOS this week: gene mutation linked to inherited venous thrombosis, lncRNA patterns in the Asian tiger mosquito, and more.